HeartSciences (NASDAQ:HSCS) Price Target Raised to $9.20 at Ascendiant Capital Markets

HeartSciences (NASDAQ:HSCS) had its price target raised by Ascendiant Capital Markets from $9.00 to $9.20 in a report published on Monday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Several other brokerages have also recently commented on HSCS. Wall Street Zen raised HeartSciences from a “sell” rating to a “hold” rating in a report on Friday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, HeartSciences presently has an average rating of “Hold” and a consensus target price of $9.20.

HeartSciences Stock Down 0.8%

HSCS stock opened at $2.34 on Monday. The company has a 50-day simple moving average of $2.85 and a 200 day simple moving average of $3.37. The company has a market capitalization of $7.44 million, a P/E ratio of -0.34 and a beta of 2.57. HeartSciences has a fifty-two week low of $2.01 and a fifty-two week high of $6.47.

HeartSciences (NASDAQ:HSCS) last released its quarterly earnings results on Monday, December 15th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.05. The company had revenue of $2.42 million for the quarter, compared to the consensus estimate of $0.00 million. Equities analysts anticipate that HeartSciences will post -10.01 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC acquired a new stake in shares of HeartSciences Inc. (NASDAQ:HSCS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 17.24% of the company’s stock.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.